SV2018005714A - Composiciones y metodos para disminuir la expresion de tau - Google Patents

Composiciones y metodos para disminuir la expresion de tau

Info

Publication number
SV2018005714A
SV2018005714A SV2018005714A SV2018005714A SV2018005714A SV 2018005714 A SV2018005714 A SV 2018005714A SV 2018005714 A SV2018005714 A SV 2018005714A SV 2018005714 A SV2018005714 A SV 2018005714A SV 2018005714 A SV2018005714 A SV 2018005714A
Authority
SV
El Salvador
Prior art keywords
compositions
methods
tau expression
decrease
decrease tau
Prior art date
Application number
SV2018005714A
Other languages
English (en)
Spanish (es)
Inventor
Ofengeim Manuela Polydoro
Jan Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SV2018005714A publication Critical patent/SV2018005714A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SV2018005714A 2015-12-21 2018-06-18 Composiciones y metodos para disminuir la expresion de tau SV2018005714A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562270165P 2015-12-21 2015-12-21

Publications (1)

Publication Number Publication Date
SV2018005714A true SV2018005714A (es) 2018-09-10

Family

ID=57758674

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005714A SV2018005714A (es) 2015-12-21 2018-06-18 Composiciones y metodos para disminuir la expresion de tau

Country Status (40)

Country Link
US (2) US11473083B2 (enExample)
EP (3) EP4678748A2 (enExample)
JP (4) JP7027328B2 (enExample)
KR (2) KR20250112919A (enExample)
CN (2) CN109072237B (enExample)
AR (1) AR107579A1 (enExample)
AU (2) AU2016376034B2 (enExample)
CA (1) CA3008094A1 (enExample)
CL (3) CL2018001652A1 (enExample)
CO (1) CO2018006297A2 (enExample)
CR (1) CR20200609A (enExample)
CU (1) CU24574B1 (enExample)
DK (1) DK3394259T3 (enExample)
DO (1) DOP2018000151A (enExample)
EA (2) EA202091865A1 (enExample)
EC (1) ECSP18050575A (enExample)
ES (1) ES2984631T3 (enExample)
FI (1) FI3394259T3 (enExample)
HR (1) HRP20240672T1 (enExample)
HU (1) HUE066548T2 (enExample)
IL (3) IL296844B2 (enExample)
JO (2) JOP20200228A1 (enExample)
LT (1) LT3394259T (enExample)
MA (2) MA71468A (enExample)
MX (2) MX2018007726A (enExample)
MY (1) MY191737A (enExample)
PE (2) PE20181448A1 (enExample)
PH (1) PH12018501207B1 (enExample)
PL (1) PL3394259T3 (enExample)
PT (1) PT3394259T (enExample)
RS (1) RS65535B1 (enExample)
RU (1) RU2747734C2 (enExample)
SA (1) SA518391831B1 (enExample)
SG (2) SG11201804704PA (enExample)
SI (1) SI3394259T1 (enExample)
SV (1) SV2018005714A (enExample)
TW (2) TWI787163B (enExample)
UY (1) UY37038A (enExample)
WO (1) WO2017109679A1 (enExample)
ZA (1) ZA201803661B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2831231A1 (en) 2012-03-30 2015-02-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
EP3922637A1 (en) * 2018-03-13 2021-12-15 Janssen Pharmaceutica NV Modified oligonucleotides for use in treatment of tauopathies
US11279929B2 (en) 2018-07-03 2022-03-22 Hoffmann-La Roche, Inc. Oligonucleotides for modulating Tau expression
CA3178304A1 (en) * 2020-03-30 2021-10-07 Alnylam Pharmaceuticals, Inc. Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof
CN113817728A (zh) * 2020-06-19 2021-12-21 四川大学华西医院 一种有效干扰Tau蛋白表达的重组慢病毒及其应用
JP2024523265A (ja) * 2021-06-16 2024-06-28 エンピリコ インク． Ｍｔｒｅｓ１関連の疾患および障害の処置
EP4370680A4 (en) * 2021-07-16 2025-08-13 Aptah Bio Inc POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR REGULATING GENE EXPRESSION
KR20240067943A (ko) 2021-09-24 2024-05-17 알닐람 파마슈티칼스 인코포레이티드 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
EP4608981A1 (en) * 2022-10-25 2025-09-03 Empirico Inc. Gene therapy treatment of mtres1 related diseases and disorders
EP4652277A1 (en) * 2023-01-18 2025-11-26 Aptah Bio, Inc. Polynucleotide compositions and methods for treatment of neurodegenerative diseases
WO2024155740A1 (en) * 2023-01-18 2024-07-25 Aptah Bio, Inc. Polynucleotide compositions and methods for treatment of cancer
CN121285630A (zh) * 2023-04-20 2026-01-06 阿达尔克斯制药有限公司 Mapt调节组合物及其使用方法
WO2025188990A1 (en) * 2024-03-08 2025-09-12 Eli Lilly And Company Mapt antisense oligonucleotide
US20250302980A1 (en) * 2024-03-31 2025-10-02 Arrowhead Pharmaceuticals, Inc. RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DE69133405T2 (de) 1990-01-11 2005-07-07 Isis Pharmaceutical, Inc., Carlsbad Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US20020052331A1 (en) 1990-08-14 2002-05-02 Brenda Baker Compositions and methods for antisense inhibition of protein translation
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
KR100199247B1 (ko) * 1992-10-05 1999-06-15 파샬 비. 린네 Ras 유전자의 안티센스 올리고뉴클레오티드 저해
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
EP0698092B1 (en) 1993-05-11 2007-07-25 The University Of North Carolina At Chapel Hill Antisense oligonucleotides which combat aberrant splicing and methods of using the same
CZ243498A3 (cs) 1996-02-14 1999-09-15 Isis Pharmaceuticals, Inc. Oligonukleotidy s mezerou a modifikovaným cukrem
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
AU3875599A (en) 1998-05-01 1999-11-23 Mayo Foundation For Medical Education And Research Pathogeniv tau mutations
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
TW200728465A (en) * 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
TR200102328T2 (tr) 1999-02-12 2002-01-21 Sankyo Company Limited Yeni nükleosid ve oligonükleotid analogları
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
AU4471700A (en) 1999-04-26 2000-11-10 University Of North Carolina At Chapel Hill, The Antisense human fucosyltransferase sequences and methods of use thereof
KR100782896B1 (ko) 1999-05-04 2007-12-06 엑시콘 에이/에스 Ｌ-리보-ｌｎａ 유사체
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
CN101284873A (zh) * 1999-06-30 2008-10-15 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
EP1248518A2 (en) 2000-01-21 2002-10-16 PHARMACIA & UPJOHN COMPANY Transgenic mouse model of human neurodegenerative disease
MXPA02008239A (es) * 2000-02-28 2004-08-12 Decode Genetics Ehf Gen humano de la esquizofrenia.
WO2002055681A2 (en) 2001-01-11 2002-07-18 Bayer Ag Regulation of human tau-tubulin kinase
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US20050130924A1 (en) 2002-06-26 2005-06-16 Monia Brett P. Antisense inhibition via RNAse H-independent reduction in mRNA
WO2004003134A2 (en) 2002-06-26 2004-01-08 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7906326B2 (en) 2003-05-07 2011-03-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20070077553A1 (en) 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20130130231A1 (en) 2002-11-26 2013-05-23 Isaac Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
KR20110007263A (ko) 2003-08-28 2011-01-21 노파르티스 아게 블런트-말단 및 3＇-변형체를 갖는 간섭 ｒｎａ 이중나선
JPWO2005030959A1 (ja) * 2003-09-25 2006-12-07 千葉県 神経芽細胞腫予後診断のためのマイクロアレイと神経芽細胞腫予後診断方法
WO2005040382A2 (de) 2003-10-28 2005-05-06 Alexander Cherkasky Cherkasky - fusionsproteine enthaltend antikorperbinde-, antigenbinde - mikrotubulibinde und immunantwortauslosende
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
IL179285A (en) * 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
US7312035B2 (en) 2004-09-03 2007-12-25 Affymetrix, Inc. Methods of genetic analysis of yeast
AU2005311601B2 (en) 2004-12-03 2011-12-01 Rhode Island Hospital Diagnosis and treatment of Alzheimer's Disease
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US20070048756A1 (en) 2005-04-18 2007-03-01 Affymetrix, Inc. Methods for whole genome association studies
US8501703B2 (en) 2005-08-30 2013-08-06 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US8258109B2 (en) 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
US20090280110A1 (en) 2006-06-27 2009-11-12 University Of Virginia Patent Foundation Cell Model for Alzheimer's Disease Pathology
US20100021914A1 (en) 2006-11-23 2010-01-28 Querdenker Aps Oligonucleotides for modulating target rna activity
CA2682497C (en) 2007-04-05 2017-08-08 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2011057350A1 (en) 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies
WO2011094645A1 (en) 2010-01-28 2011-08-04 University Of Massachusetts Lowell Methods of diagnosing tau-associated neurodegenerative diseases
WO2011117353A1 (en) 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012069059A1 (en) 2010-11-23 2012-05-31 Mirrx Therapeutics A/S Oligonucleotides for modulation of target rna activity
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012149438A1 (en) * 2011-04-28 2012-11-01 Life Technologies Corporation Methods and compositions for multiplex pcr
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
EP2831231A1 (en) 2012-03-30 2015-02-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
MX2014014894A (es) 2012-06-04 2015-02-20 Irm Llc Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
CN104936977B (zh) 2012-10-24 2019-10-08 开普敦大学 微管修饰化合物
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
HK1216902A1 (zh) 2012-12-20 2016-12-09 Sarepta Therapeutics, Inc. 用作治疗肌肉萎缩的改进外显子跳跃组合物
KR20240094032A (ko) 2013-03-14 2024-06-24 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 엑손 스키핑 조성물
JP6449231B2 (ja) 2013-03-14 2019-01-09 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
US9644207B2 (en) * 2013-03-14 2017-05-09 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
CA2951816A1 (en) 2013-06-12 2014-12-18 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
TWI772856B (zh) * 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2015068075A2 (en) 2013-10-24 2015-05-14 Institut National De La Sante Et De La Recherche Medicale Detection of tau
CN104711324A (zh) * 2013-12-11 2015-06-17 芮屈生物技术（上海）有限公司 老年性痴呆病变前期TAU基因的mRNA水平原位杂交筛查试剂盒
WO2016011123A1 (en) * 2014-07-16 2016-01-21 Arrowhead Research Corporation Organic compositions to treat apoc3-related diseases
WO2016019063A1 (en) 2014-07-29 2016-02-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
EP3254104B1 (en) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
US20180023081A1 (en) 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
MA41586A (fr) * 2015-02-04 2017-12-13 Hoffmann La Roche Oligomères antisens de la protéine tau et leurs utilisations
US20170035860A1 (en) * 2015-04-02 2017-02-09 Alexander C. Flynn Compositions and methods for treatment of neurogenerative diseases

Also Published As

Publication number Publication date
EP3394259B1 (en) 2024-02-28
EA202091865A1 (ru) 2021-01-29
CN109072237B (zh) 2022-12-16
JOP20200228A1 (ar) 2017-06-16
UY37038A (es) 2017-07-31
EA036417B1 (ru) 2020-11-09
CU20180065A7 (es) 2018-11-06
CU24574B1 (es) 2022-01-13
ZA201803661B (en) 2024-08-28
KR20250112919A (ko) 2025-07-24
RS65535B1 (sr) 2024-06-28
JO3790B1 (ar) 2021-01-31
FI3394259T3 (fi) 2024-05-24
IL296844B2 (en) 2024-04-01
HUE066548T2 (hu) 2024-08-28
JP2025026976A (ja) 2025-02-26
RU2018126545A (ru) 2020-01-23
AU2020267282B2 (en) 2023-05-18
EP4406541A2 (en) 2024-07-31
TWI834177B (zh) 2024-03-01
US20220411796A1 (en) 2022-12-29
MX2023008211A (es) 2023-07-18
MA44426B1 (fr) 2024-05-31
JP7594557B2 (ja) 2024-12-04
PT3394259T (pt) 2024-05-20
AR107579A1 (es) 2018-05-16
KR102834468B1 (ko) 2025-07-15
HK1254822A1 (en) 2019-07-26
PE20241069A1 (es) 2024-05-13
SG11201804704PA (en) 2018-07-30
DK3394259T3 (da) 2024-05-27
CL2019003420A1 (es) 2020-05-15
RU2021112980A (ru) 2021-05-28
IL296844A (en) 2022-11-01
JP2022065096A (ja) 2022-04-26
RU2018126545A3 (enExample) 2020-10-12
SG10201913434PA (en) 2020-03-30
RU2021112980A3 (enExample) 2021-12-28
PH12018501207A1 (en) 2019-02-11
EP3394259A1 (en) 2018-10-31
IL260124A (en) 2018-07-31
KR20180089517A (ko) 2018-08-08
SA518391831B1 (ar) 2022-08-16
JP2019500428A (ja) 2019-01-10
TW202311530A (zh) 2023-03-16
IL305866B2 (en) 2024-12-01
PE20181448A1 (es) 2018-09-12
US11473083B2 (en) 2022-10-18
ECSP18050575A (es) 2018-07-31
WO2017109679A1 (en) 2017-06-29
CR20200609A (es) 2021-02-17
NZ783034A (en) 2025-07-25
EP4678748A2 (en) 2026-01-14
CL2019000149A1 (es) 2019-06-07
JP2021118732A (ja) 2021-08-12
CO2018006297A2 (es) 2018-07-10
CA3008094A1 (en) 2017-06-29
NZ743231A (en) 2025-07-25
IL305866A (en) 2023-11-01
IL305866B1 (en) 2024-08-01
TWI787163B (zh) 2022-12-21
HRP20240672T1 (hr) 2024-08-16
AU2016376034A1 (en) 2018-07-05
BR112018012304A2 (pt) 2019-02-05
IL296844B1 (en) 2023-12-01
DOP2018000151A (es) 2018-09-15
AU2020267282A1 (en) 2020-12-10
MA71468A (fr) 2025-04-30
LT3394259T (lt) 2024-06-10
MY191737A (en) 2022-07-13
AU2016376034B2 (en) 2020-12-03
EA201891468A1 (ru) 2018-12-28
CN116218848A (zh) 2023-06-06
ES2984631T3 (es) 2024-10-30
CL2018001652A1 (es) 2018-08-10
SI3394259T1 (sl) 2024-07-31
EP4406541A3 (en) 2024-10-16
PL3394259T3 (pl) 2024-07-22
RU2747734C2 (ru) 2021-05-13
CN109072237A (zh) 2018-12-21
TW201733597A (zh) 2017-10-01
JP7027328B2 (ja) 2022-03-01
PH12018501207B1 (en) 2024-02-23
US20170175116A1 (en) 2017-06-22
MX2018007726A (es) 2018-08-15

Similar Documents

Publication Publication Date Title
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
MX377141B (es) Composiciones y metodos para modular la expresion de pkk.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY36021A (es) Proteìnas fc multimèricas
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
EP3373962A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCER DISEASES
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
EA201791937A1 (ru) Противовоспалительные полипептиды
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
MX383460B (es) Derivados peptidicos novedosos y sus usos.
EP3362085C0 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES INVOLVING MUCIN